Ulf Björklund joins the TikoMed board
Written on 2016-07-02
Mr. Ulf Björklund was unanimously elected to the board of TikoMed at the annual meeting held in Höganäs on the 16th of June. Ulf had a long career in Pharmacia until 2002 when he joined Oxypharma as CEO. He was then recruited to Aprea AB also as CEO.
Ulf has experienced great successes in managing partner collaborations, financing and clinical development.
The TikoMed Chairman, Stefan Sallerfors: “Mr. Björklund has vast experience and knowledge from operational company development and business. He will constitute a central addition to TikoMed present intense development process with a distinctive focus on achieving value inflection points and exit. We are very pleased to welcome him to our board.”
Mr. Björklund: ”I want to thank the shareholders of TikoMed AB for this confidence. I have studied TikoMed and the projects for some time and I am thoroughly looking forward to bringing this unique and highly interesting project to success. Its commercial potential is very attractive for a ”Big Pharma”. I and the board will from hereon put every effort into delivering an exit.”
TikoMed AB, develops products for the pharmaceutical specialist segment. Presently the focus is on TM-700 which has shown unique properties in treating ischemic diseases where there is a large medical need and no effective pharmaceutical treatments options. The project is being prepared to enter Phase 2 in parallel with a very active discussion with potential partners.
The company is privately held by a relatively small group of shareholders. Stefan Sallerfors, MD., is Chairman. He has extensive experience from the Swedish health care system and the financial sector. Anders Waas, DDS., is CEO and has previously held leading business development positions at Astra/AstraZeneca, CV Therapeutics and Actogenics.
För ytterligare kommentarer vänligen kontakta / For further comments please contact:
Stefan Sallerfors, Ordförande